OptimizeRx Corporation (NASDAQ:OPRX) Q2 2025 Earnings Call Transcript
Operator: Good afternoon, everyone, and thank you for joining OptimizeRx's Second Quarter Fiscal 2025 Earnings Conference Call.
Optimizerx Corp (OPRX)
Market is closed
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Whetstone Capital Advisors David Atterbury | 1,508,303 | $20,362,091 | 5.75% | |
| 2. | Royce & Associates Chuck Royce | 790,640 | $10,673,640 | -21% | 0.11% |
| 3. | Parkman Healthcare Partners Greg Martinez | 507,423 | $6,850,211 | +7% | 0.79% |
| 4. | Manatuck Hill Partners Mark Broach | 455,000 | $6,142,500 | +140% | 2.31% |
| 5. | D E Shaw D. E. Shaw | 412,896 | $5,574,096 | +18% | 0% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $7.60 | 321,408 | $2,443,761.45 | 389,452 | 2025-03-14 | Filing | |
| $5.01 | 20,000 | $100,220.00 | 601,253 | 2024-12-12 | Filing | |
| $15.75 | 1,000 | $15,750.00 | 5,000 | 2022-08-26 | Filing | |
| $16.45 | 6,000 | $98,723.40 | 38,660 | 2022-08-19 | Filing | |
| $15.29 | 10,700 | $163,641.52 | 461,772 | 2022-08-22 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $15.19 | 4,000 | $60,750.80 | 11,114 | 2024-01-09 | Filing | |
| $44.96 | 400 | $17,984.00 | 445,672 | 2022-02-18 | Filing | |
| $44.12 | 7,066 | $311,766.05 | 446,072 | 2022-02-18 | Filing | |
| $43.38 | 9,200 | $399,086.80 | 453,138 | 2022-02-18 | Filing | |
| $48.52 | 300 | $14,556.90 | 462,338 | 2022-01-18 | Filing |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 1,221,833 | $16,494,748 | 0% | |
| 2. | 920,885 | $12,431,948 | 0% | |
| 3. | 628,926 | $8,490,504 | 0.02% | |
| 4. | 607,560 | $8,202,060 | 0.44% | |
| 5. | 472,472 | $6,378,372 | 0.15% |
News See All
OptimizeRx Corporation (NASDAQ:OPRX) Q1 2025 Earnings Call Transcript
Operator: Good afternoon, everyone, and thank you for joining OptimizeRx First Quarter Fiscal 2025 Earnings Conference Call.
OptimizeRx Corporation (NASDAQ:OPRX) Q4 2024 Earnings Call Transcript
Operator: Good morning, everyone, and thank you for joining OptimizeRx's Fourth Quarter and Full Year Fiscal 2024 Earnings Conference Call. With us today is Chief Executive Officer, Steve Silvestro.
OptimizeRx Corporation (NASDAQ:OPRX) Q3 2024 Earnings Call Transcript
Operator: Good afternoon, everyone, and thank you for joining OptimizeRx's Third Quarter Fiscal 2024 Earnings Call. With us today is OptimizeRx's Chief Executive Officer, William Febbo.
OptimizeRx Corporation (NASDAQ:OPRX) Q2 2024 Earnings Call Transcript
Operator: Good afternoon, everyone, and thank you for joining OptimizeRx's Second Quarter Fiscal 2024 Earnings Call. With us today is the Chief Executive Officer of OptimizeRx, William Febbo.
OptimizeRx Corporation (NASDAQ:OPRX) Q1 2024 Earnings Call Transcript
Operator: Good afternoon, everyone, and thank you for joining OptimizeRx's First Quarter Fiscal 2024 Earnings discussion. With us today is the Chief Executive Officer of OptimizeRx, William Febbo.
OptimizeRx Corporation (NASDAQ:OPRX) Q4 2023 Earnings Call Transcript
Operator: Good morning, everyone and thank you for joining OptimizeRx’s Fourth Quarter Fiscal 2023 Conference Call. With us today is the Chief Executive Officer of OptimizeRx, William Febbo.
Should You Exit OptimizeRx Corp. (OPRX)?
Wasatch Global Investors, an investment management firm, released its “Wasatch Micro Cap Value Strategy” third quarter 2023 investor letter. A copy of the same can be downloaded here.
OptimizeRx Corporation (NASDAQ:OPRX) Q3 2023 Earnings Call Transcript
Operator: Good morning, everyone and thank you for joining OptimizeRx’s Third Quarter Fiscal 2023 Earnings Discussion. With us today is the Chief Executive Officer of OptimizeRx, William Febbo.
OptimizeRx Corporation (NASDAQ:OPRX) Q2 2023 Earnings Call Transcript
Operator: Good afternoon, everyone. And thank you for joining OptimizeRx’s Second Quarter Fiscal 2023 Earnings Discussion. With us today is the Chief Executive Officer of OptimizeRx, William Febbo.
Billionaire Hedge Funds
